PMID- 34440727
OWN - NLM
STAT- MEDLINE
DCOM- 20211111
LR  - 20240403
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 10
IP  - 8
DP  - 2021 Aug 1
TI  - The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current 
      Evidence and Underlying Mechanisms.
LID - 10.3390/cells10081958 [doi]
LID - 1958
AB  - The age-related decrease in skeletal muscle mass together with the loss of muscle 
      power and function is defined sarcopenia. Mounting evidence suggests that the 
      prevalence of sarcopenia is higher in patients with type 2 diabetes mellitus 
      (T2DM), and different mechanisms may be responsible for this association such as 
      impaired insulin sensitivity, chronic hyperglycemia, advanced glycosylation end 
      products, subclinical inflammation, microvascular and macrovascular 
      complications. Glucose-lowering drugs prescribed for patients with T2DM might 
      impact on these mechanisms leading to harmful or beneficial effect on skeletal 
      muscle. Importantly, beyond their glucose-lowering effects, glucose-lowering 
      drugs may affect per se the equilibrium between protein anabolism and catabolism 
      through several mechanisms involved in skeletal muscle physiology, contributing 
      to sarcopenia. The aim of this narrative review is to provide an update on the 
      effects of glucose-lowering drugs on sarcopenia in individuals with T2DM, 
      focusing on the parameters used to define sarcopenia: muscle strength (evaluated 
      by handgrip strength), muscle quantity/quality (evaluated by appendicular lean 
      mass or skeletal muscle mass and their indexes), and physical performance 
      (evaluated by gait speed or short physical performance battery). Furthermore, we 
      also describe the plausible mechanisms by which glucose-lowering drugs may impact 
      on sarcopenia.
FAU - Massimino, Elena
AU  - Massimino E
AD  - Department of Clinical Medicine and Surgery, Federico II University, Via Sergio 
      Pansini 5, 80131 Naples, Italy.
FAU - Izzo, Anna
AU  - Izzo A
AD  - Department of Clinical Medicine and Surgery, Federico II University, Via Sergio 
      Pansini 5, 80131 Naples, Italy.
FAU - Riccardi, Gabriele
AU  - Riccardi G
AD  - Department of Clinical Medicine and Surgery, Federico II University, Via Sergio 
      Pansini 5, 80131 Naples, Italy.
FAU - Della Pepa, Giuseppe
AU  - Della Pepa G
AUID- ORCID: 0000-0001-5862-3794
AD  - Department of Clinical Medicine and Surgery, Federico II University, Via Sergio 
      Pansini 5, 80131 Naples, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210801
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Protease Inhibitors)
RN  - 0 (Thiazolidinediones)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Diabetes Mellitus, Type 2/complications/drug therapy/*pathology
MH  - Glycation End Products, Advanced/metabolism
MH  - Hand Strength
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Metformin/therapeutic use
MH  - Muscle, Skeletal/physiology
MH  - Protease Inhibitors/therapeutic use
MH  - Sarcopenia/*complications
MH  - Thiazolidinediones/therapeutic use
PMC - PMC8393336
OTO - NOTNLM
OT  - glucose-lowering drugs
OT  - sarcopenia
OT  - skeletal muscle index
OT  - skeletal muscle mass
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflict of interest.
EDAT- 2021/08/28 06:00
MHDA- 2021/11/12 06:00
PMCR- 2021/08/01
CRDT- 2021/08/27 01:07
PHST- 2021/06/30 00:00 [received]
PHST- 2021/07/25 00:00 [revised]
PHST- 2021/07/29 00:00 [accepted]
PHST- 2021/08/27 01:07 [entrez]
PHST- 2021/08/28 06:00 [pubmed]
PHST- 2021/11/12 06:00 [medline]
PHST- 2021/08/01 00:00 [pmc-release]
AID - cells10081958 [pii]
AID - cells-10-01958 [pii]
AID - 10.3390/cells10081958 [doi]
PST - epublish
SO  - Cells. 2021 Aug 1;10(8):1958. doi: 10.3390/cells10081958.